BlackBoxRX
 
We highly recommend enabling Javascript while using the BlackBoxRX site.

Olodaterol/Tiotropium

Asthma-Related Death

  • Long-acting beta2-adrenergic agonists (LABA) such as olodaterol, one of the active ingredients in STIOLTO RESPIMAT, increase the risk of asthma-related death. Data from a large, placebo-controlled US study that compared the safety of another long-acting beta2-adrenergic agonist (salmeterol) with placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol. This finding with salmeterol is considered a class effect of all LABA, including olodaterol, one of the active ingredients in STIOLTO RESPIMAT. The safety and efficacy of STIOLTO RESPIMAT in patients with asthma have not been established. STIOLTO RESPIMAT is not indicated for the treatment of asthma¬†

Patient Counseling Information

Medication Guides

Patient Medication Guide

Package Inserts

Olodaterol/Tiotropium

Updated January 2018